StockData
CytoMed Therapeutics Ltd logo

CytoMed Therapeutics Ltd (GDTC) stock

GDTCNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 31, 2026Score 4/30
$0.83+0.05 (+6.00%)

Close on Nov 18, 2026Market cap $9.82MP/E –Yield –

CytoMed Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

No operating income figures for CytoMed Therapeutics

CytoMed Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More CytoMed Therapeutics figures

See a number that looks wrong?